R&D Trends

Juno partners Memorial Sloan Kettering and Eureka Therapeutics

Tuesday, August 9, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, has entered into an exclusive license agreement with Memorial Sloan-Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma.

[Read More]

Regeneron, Adicet Bio collaborate on immune cell therapeutics

Wednesday, August 3, 2016

Regeneron Pharmaceuticals and Adicet Bio have announced a collaboration and licensing agreement to develop next-generation engineered immune cell therapeutics. The companies plan to engineer immune cells with fully human chimeric antigen receptors (CARs) and T-cell receptors (TCRs) directed to disease-specific cell surface antigens in order to enable the precise engagement and killing of tumor cells. The collaboration is intended to generate multiple clinical product candidates for various hematological and solid tumor cancers.

[Read More]

Altimmune receives $120M BARDA contract for Anthrax vaccine candidate Nasoshield

Wednesday, August 3, 2016

Altimmune, a clinical stage immunotherapeutic company, was awarded a contract valued at up to $120.2 million over five years from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to fund the clinical development of NasoShield, its first-in-class anthrax vaccine candidate. Under BARDA contract HHSO100201600008C, Altimmune has been awarded $14.3 million under the base contract to fund its phase I trial for NasoShield, and options to receive up to an additional $105.9 million to fund further preclinical, clinical and manufacturing development activities. 

[Read More]

NIH funds precision medicine research with a focus on health disparities

Friday, July 29, 2016

The National Institute on Minority Health and Health Disparities (NIMHD), part of the NIH, has committed approximately $31 million over five years, pending available funding, to launch a new program for Transdisciplinary Collaborative Centers (TCCs) for health disparities research exploring the potential for precision medicine to promote health equity and advance the science of minority health and health disparities.

[Read More]

Embera wins $11M NIDA grant for cocaine addiction treatment EMB-001

Wednesday, July 27, 2016

Embera NeuroTherapeutics, a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the NIH. The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”

[Read More]

Wiley launches Wiley Spectra Lab

Tuesday, July 26, 2016

Wiley has launched Wiley Spectra Lab, a new and flexible expert spectral data system that uses empirical data and advanced software to help chemists, toxicologists, and life scientists confidently identify chemical substances. Wiley Spectra Lab provides access to these data in a convenient, secure cloud environment.

[Read More]

AbbVie, Bristol-Myers Squibb ink oncology clinical collaboration

Tuesday, July 26, 2016

AbbVie and Bristol-Myers Squibb have announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a treatment for relapsed extensive-stage small cell lung cancer (SCLC).

[Read More]